Eur J Gynaecol Oncol. 2016;37(3):342-7.
Pterostilbene induces apoptosis through caspase activation in ovarian cancer cells.
Pterostilbene, an analog of resveratrol increasing bioavailability has shown to offer antioxidant and anticancer properties in vitro and in vivo. Dietary compounds with anti-oxidant properties have been shown to gain importance due to therapeutic applications. In addition, compounds with higher bioavailability levels show great interest in present scenario. Thus, the present study aimed at investigating the cytotoxic role of pterostilbene and its mechanism of cell death in ovarian cancer cells line.
MATERIALS AND METHODS:
The effect of pterostilbene was determined on SKOV-3 cells, by cytotoxicity assays, oxidative stress levels, [Ca2+]i levels, mitochondrial depolarization, cell cycle analysis and caspase 3, 8, and 9 activities.
The study revealed that pterostilbene offered cytotoxic effect at a concentration of IC50-55 uM. Further, pterostilbene induced reactive oxygen species (ROS) mediated intrinsic pathway of apoptosis through enhancing oxidative stress, [Ca2+]i levels, mitochondrial depolarization, Sub G1 accumulation, and activation of caspase 3 and 9.
The study demonstrates for the first time the cytotoxic potential of pterostilbene against ovarian cancer cells.
Med Sci Monit. 2017 Jun 30;23:3192-3199.
Anticancer Activity of Pterostilbene in Human Ovarian Cancer Cell Lines.
Epithelial ovarian cancer is a major cause of mortality in women and one of the most common gynecologic disorders. Pterostilbene (PTS), a trans-3,5-dimethoxy-4′-hydroxystilbene, was chosen for this work due to its reported effectiveness as a chemotherapeutic agent in cancer studies. In this work, we studied underlying molecular mechanisms of PTS treatment in various ovarian cancer cell lines such as OVCAR8, OV1063, IGROV-1, and SKOV3. MATERIAL AND METHODS We used the cytometric bead array (CBA) method and real-time PCR analysis to analyze the secretion level of tumor necrosis factor alpha (TNF-α) and to measure the TNF-α mRNA expression. NF-kappa B (NF-κB) promoter analysis, Western blot analysis, electrophoresis mobility shift assay (EMSA), and immunostaining analyses were performed to measure the NF-κB activity and other relative proteins levels. RESULTS The PTS treatment decreased the release of TNF-α in IGROV-1 ovarian cancer cells. It also showed significant inhibitory effect on nuclear NF-κB p50, and NF-κB p65 protein levels. CONCLUSIONS From the results obtained, we suggest that PTS has the potential to treat ovarian cancer by reducing the level of TNF-α cytokine and to have a limited effect on NF-κB, AKT, and ERK signaling pathways.